Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Phase 3 Trials for PsA: Achievement of Minimal Disease Activity, Individual Components, and Very Low Disease Activity Through Week 52 (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2291; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; No abstract available
Clinical • P3 data • Ankylosing Spondylitis • Immunology • Psoriasis • Psoriatic Arthritis • Rheumatology • Spondylarthritis • TYK2
|